Carbiotix AB
19 May - 2 Jun 2022Rights issue
Carbiotix provides, through its research and development of products, medicines that increases the production of good bacteria from the intestine to counteract several different metabolic and chronic diseases. The products are based on the Company’s own beneficial bacterial strains in combination with proprietary soluble fibers as well as innovative ways to develop these medicine substances. The company currently conducts research and development and sells products and services in primarily four business areas: Diagnosis of intestinal health, prebiotic ingredients, medical food and therapeutic treatments. The company was founded in 2014 and is headquartered in Lund.
Read more on the company's website
The offer in summary
Record date: 13 May 2022
Subscription period: 19 May - 2 June 2022
Subscription rights: Anyone who is a shareholder on the record date of 13 May 2022 has preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unitright. Thirty-four (34) unitrights entitles to subscription of one (1) unit. Each unit consists of seven (7) newly issued shares and seven (7) warrants of series TO 1.
Subcription price: SEK 55.30
Emission volume: Maximum of 362 753 units which corresponds to about MSEK 20
Trading with unitrights: 19 May - 30 May 2022
Marketplace: Spotlight Stock Market
Financial advisor: Sedermera Corporate Finance
Subscribe via Avanza here.
Subscribe via Nordnet here.
